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Background: In 2002, a new diagnostic strategy in symptomatic outpatients without known 
established colorectal cancer risk factors aged 40 years or older was implemented in Denmark. 
Fecal occult blood test (Hemoccult Sensa®) was a part of that strategy in patients without visible 
rectal bleeding.
Aims: The aim was to assess the validity of the Hemoccult Sensa® test in detecting colorectal 
cancer in the above-mentioned outpatients.
Patients: Symptomatic outpatients without known established colorectal cancer risk factors 
and without visible rectal bleeding.
Methods: Hemoccult Sensa® was performed before endoscopic examination. Colorectal cancer 
was identified at histopathological examination. Patients completed a questionnaire about their 
symptoms before their first hospital appointment.
Results: Eight of 256 patients were found to have colorectal cancer. Median patient age was 
63 years. The positive predictive value, negative predictive value, sensitivity, and specificity of 
Hemoccult Sensa® for colorectal cancer were 10.5% (95% confidence interval [CI]: 6.8–14.3), 
99.0% (95% CI: 97.8–100.0), 75.0% (95% CI: 69.7–80.3), and 79.4% (95% CI: 74.5–84.4).
Conclusions: Hemoccult Sensa® as the initial examination in symptomatic outpatients without 
known established colorectal cancer risk factors presenting without rectal bleeding has to be 
used with caution. We did not find Hemoccult Sensa® test to be an acceptable alternative to 
flexible sigmoidoscopy.
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Introduction
Colorectal cancer (CRC) is one of the most common cancers in Westernized 
countries1,2 and the number of cases is expected to rise as the population ages.3 
The vast majority of CRCs are found in patients without established CRC risk 
factors4 who are diagnosed upon onset of symptoms or through routine screening. 
In Denmark, screening for CRC is not offered to the general public. In 2002, a new 
diagnostic strategy in symptomatic outpatients without known established CRC risk 
factors aged 40 or older and referred by general practitioners was implemented in 
Denmark. A fecal occult blood test (FOBT, Hemoccult Sensa®; Beckman Coulter 
Gmbh, Krefeld, Germany) was a part of the strategy in patients without visible rectal 
bleeding. Symptoms indicative of CRC – changes in bowel habits, abdominal pain. 
and unintentional loss of weight – are also prevalent both in the general population 
and in patients with benign disease,5–9 differentiation between patients with CRC and 
those with benign disease is difficult. Using patient history alone as an indication Clinical Epidemiology 2009:1 120
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of  CRC may lead many patients with benign conditions to 
undergo endoscopic examinations. Hemoccult Sensa® could 
be used as the initial diagnostic procedure for symptomatic 
outpatients without visible rectal bleeding.10
Earlier studies of the usefulness of FOBT in detecting 
CRC among symptomatic patients reported sensitivities 
ranging from 69% to 100%, specificities ranging from 73% 
to 89%, and positive predictive values ranging from 7% to 
76%.10–14 These studies either evaluated the Hemoccult and 
Hemoccult II tests, which are less sensitive to fecal blood 
than Hemoccult Sensa®, and/or did not take into consideration 
reason for colonoscopy referral (eg, symptoms or routine 
surveillance), risk profile (patients with vs patients without 
established CRC risk factors), or presence of visible rectal 
bleeding. We aimed to access the validity of Hemoccult 
Sensa® in symptomatic outpatients without known estab-
lished CRC risk factors aged 40 years or older presenting 
without visible rectal bleeding, and who were referred by 
general practitioners, by estimating the sensitivity, specificity, 
and predictive values of Hemoccult Sensa® for CRC.
Patients and methods
This observational study took place in the surgical outpatient 
clinics at two public Danish hospitals in Aarhus County, 
Denmark (Randers Central Hospital [RCH] and Aarhus 
University Hospital [AUH]). These clinics are the primary 
referral centers in the two hospitals’ catchment areas for 
patients with symptoms consistent with CRC.
As of January 1st, 2003, about 91% of the 433,000 
residents in the two hospitals’ catchment areas were of 
Danish origin. The entire population of Denmark receives 
tax-supported health care from the National Health 
Service, which allows free access to primary care (general 
practitioners) and to public hospitals. The study period was 
September 1st, 2002 to December 31st, 2003 in RCH and 
October 1st, 2002 to December 31st, 2003 in AUH.
The study was approved by the local Scientific Ethics 
Committee and Danish Data Protection Agency.
Identification of study participants
At AUH, an author (NCB) reviewed all referrals to the 
surgical outpatient clinic. At RCH, a consultant reviewed 
the referrals. At the conclusion of enrolment, NCB examined 
case notes at RCH to ensure strict adherence to inclusion and 
exclusion criteria. Patients without known established CRC 
risk factors aged 40 years or older referred by the general 
practitioners, with symptoms consistent with CRC, were 
included in the study. Patients younger than 40 years and 
those with known established CRC risk factors (history of 
CRC or colorectal adenoma, inflammatory bowel disease, 
endometrial cancer, at least one first-degree relative under 
the age of 50 years with CRC or colorectal adenoma, familial 
hereditary nonpolyposis CRC, or familial adenomatous 
polyposis) were excluded. Eligible patients received a mailed 
questionnaire covering symptoms as well as CRC history 
among first-degree relatives. Completed questionnaires 
were collected during initial appointments at AUH or RCH. 
The examining endoscopist (surgeon or nurse) recorded the 
type of procedure performed (eg, flexible sigmoidoscopy 
[FS], colonoscopy, or FOBT) along with its findings on an 
examination form.
Data from the questionnaire and the examination form 
were entered into a database. Patients who reported CRC 
in first-degree relatives younger than 50 years of age were 
excluded.
From the database, we retrieved patients with available 
Hemoccult Sensa® test results who answered “no” or “don’t 
know” to the questionnaire item about rectal bleeding in the 
past 12 months. The date of the Hemoccult Sensa® test and its 
results were obtained from the departments of  biochemistry at 
AUH and RCH. These two departments analyzed both the tests 
done by the general practitioners and the surgical outpatient 
clinics. Only patients with a Hemoccult Sensa® test performed 
within two months preceding referral, or with a Hemoccult 
Sensa® test performed as the initial investigation at the 
surgical outpatient clinics were included in the analyses.
Fecal occult blood test
The Hemoccult Sensa® test was distributed to patients either 
by their general practitioners before referral, or by hospital staff 
during the first visit to the surgical outpatient clinic. To decrease 
false-positive and false-negative rates, patients were asked 
to abstain from red meat, cauliflower, tomato, paprika, 
horseradish, banana, melon, and soya beans (peroxidase-rich 
vegetables), and to avoid large amounts of other fresh fruit and 
raw vegetables three days before collection of the first specimen 
and throughout the collection period. Except when treatment 
interruption entailed health risks, patients were also instructed 
to abstain from acetylsalicylic acid, other nonsteroidal 
anti-inflammatory drugs, adrenocortical hormones, and 
supplements containing iron and vitamin C. Stool specimens 
collected from three separate bowel movements were smeared 
on the Hemoccult Sensa® card windows and processed 
within six days of the final specimen collection.
To standardize results and facilitate data collection, 
Hemoccult Sensa® test cards from the study patients were Clinical Epidemiology 2009:1 121
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processed only by the participating hospitals’ Biochemistry 
Departments.15
Identification of patients with cancer
Endoscopic examinations
If the Hemoccult Sensa® test was negative, a FS was 
recommended; additional examinations were performed if 
indicated by symptoms and findings at FS. Patients whose 
FS revealed polyps were referred for colonoscopy. When the 
Hemoccult Sensa® test result was positive, a colonoscopy was 
recommended. If a colonoscopy was incomplete a double-
contrast barium enema (DBCE) or a virtual colonoscopy 
(VC) was performed.
All FS’s were performed either by experienced nurse-
endoscopists, surgeon-endoscopists (junior doctors and 
experienced surgeons). Colonoscopies were performed 
by experienced surgeon-endoscopists or by junior doctors 
supervised by an experienced surgeon-endoscopist.
All biopsied or excised tumors were submitted for histo-
pathological examination.
Follow up to identify missed cancers
Cases of CRC diagnosed after discharge from the surgical 
outpatient clinics and before January 1st, 2005 were consid-
ered to have been missed during the diagnostic examinations. 
To detect such missed cancers, we searched computerized 
records from the hospital discharge registries of Aarhus 
County and two adjoining counties, Viborg and North Jutland 
Counties January 1st, 2005. These registries were previ-
ously found to have high validity.16 These population-based 
administrative public registries contain data on all nonpsy-
chiatric hospital admissions since 1977, as well as data on 
outpatient and emergency visits since 1994. The registries 
include the unique personal identification numbers issued to 
all citizens of Denmark, as well as primary and secondary 
diagnoses coded by medical doctors at discharge according 
to the International Classification of Diseases (ICD). We used 
the following ICD, 10th revision (ICD-10) codes to identify 
patients with CRC at follow-up: DC18.0, DC18.2–18.9, 
DC19.9, and DC20.9.
Patients were classified as having CRC if endoscopy 
detected a malignancy (confirmed by histopathological 
examination) or if CRC were detected during the follow-up 
period (confirmed by histopathological examination).
statistical analysis
We estimated the sensitivity, specificity, positive predictive 
value (PPV), and negative predictive value (NPV) of 
Hemoccult Sensa® for CRC. Sensitivity was defined as 
the proportion of people with CRC who had a positive 
result on Hemoccult Sensa®; specificity was defined as 
the proportion of people without CRC who had a negative 
Hemoccult Sensa®; PPV was defined as the probability of 
CRC in a patient with a positive Hemoccult Sensa®; and 
NPV was defined as the probability of not having CRC given 
a negative Hemoccult Sensa® test.17 The statistical analysis 
was performed with STATA 8.0 software (Stata Corporation, 
College Station, TX, USA).
Results
Two thousand four hundred eight outpatients without 
known established CRC risk factors aged 40 years or older 
with symptoms consistent with CRC were examined in 
the two surgical outpatient clinics during the study period. 
Twenty-six were excluded due to a questionnaire reporting 
of CRC in a first-degree relative aged younger than 50 years. 
Two hundred fifty-six patients who met the inclusion criteria 
for the present study (no self-reported rectal bleeding in the 
past 12 months, Hemoccult Sensa® test as the initial investi-
gation) were retrieved from the database. The median age of 
study patients was 63 years (range 40–94 years) with 62.5% 
of the patients aged 60 years or older. One hundred and eight 
(42.2%) were men. The symptoms and signs reported by 
the patients are listed in Table 1 and the primary discharge 
diagnoses are listed in Table 2.
In 11 patients, the colonoscopy was incomplete, and 
the patients subsequently received either a DCBE or a VC. 
One patient had FS and DBCE/VC, and 120 had only FS. 
Fifty-seven of the 256 patients had a positive Hemoccult 
Sensa® test, and of these 56 underwent colonoscopy; 
the 57th patient had a cancer diagnosed at a FS. Of the 
Table 1 symptoms and signs reported by referred outpatients undergoing 
a hemoccult sensa® test as their initial examination
Symptom/sign %
Fatigue 42.9
Weight loss 21.0
Anemia 12.0
Mucus discharge 23.7
Change in frequency of bowel movements 61.3
Change in consistency of stool 72.4
Insufficient rectal emptying 50.4
Abdominal pain 62.5
Colorectal cancer in first-degree relatives 
older than 50 years of age
8.0 Clinical Epidemiology 2009:1 122
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199 patients with a negative Hemoccult Sensa® test, 119 had 
only FS, 79 had a colonoscopy, and one patient had FS and 
DBCE/VC. In total, 135 of the 256 eligible patients (52.7%) 
underwent colonoscopy.
Eight cancers were diagnosed in the 256 patients (3.1%; 
95% confidence interval [CI]: 1.4%–6.1%). The tumor stages 
(according to Dukes), sites, and Hemoccult Sensa® test 
results are listed in Table 3. Of the six patients with cancer 
and positive Hemoccult Sensa® test, one had only FS and five 
underwent colonoscopy. One patient with cancer and negative 
Hemoccult Sensa® test underwent colonoscopy when found 
to have iron deficiency anemia. The other patient with CRC 
and a negative Hemoccult Sensa® test was diagnosed at a 
DCBE following an inadequate FS.
No missed cancers were found at follow-up using the 
hospital discharge registries. Mean follow-up time was 
18.1 months (range 0.1–28.0 months).
Six of the 57 patients with a positive Hemoccult Sensa® 
test were diagnosed with CRC (Table 2). Of the 199 patients 
with a negative Hemoccult Sensa® test, two were diagnosed 
with CRC. One patient with cancer also had a large adenoma 
(10 mm or larger). Of the 248 patients without cancer, 51 had 
a positive Hemoccult Sensa® test; ten of these were diagnosed 
with an adenoma, including six patients with adenomas 
10 mm or larger. Of the 80 patients with a negative Hemoccult 
Sensa® test and complete visualization of their colons, 30 had 
an adenoma of any size (six of these were 10 mm or larger).
The PPV and NPV of Hemoccult Sensa® for CRC were 
10.5% (95% CI: 6.8–14.3) and 99.0% (95% CI: 97.8–100.0). 
Sensitivity and specificity of Hemoccult Sensa® for 
CRC were 75.0% (95% CI: 69.7–80.3) and 79.4% (95% 
CI: 74.5–84.4).
In addition to the 256 study patients without visible rectal 
bleeding who were included in the present Hemoccult Sensa® 
validation study, 735 additional patients without visible rectal 
bleeding were examined who had no Hemoccult Sensa®, 
whose test was done after an endoscopic examination, 
or whose test took place more than two months before 
referral for endoscopic examination. Of these 735 patients, 
28 (3.8%; 95% CI: 2.5–5.5) were diagnosed with CRC 
during the study period and follow-up period.
Discussion
To the best of our knowledge, this study is the first to assess 
the diagnostic validity of Hemoccult Sensa® for CRC in 
symptomatic outpatients without known established CRC risk 
factors presenting without visible rectal bleeding. We found 
Hemoccult Sensa® to perform only relatively acceptable 
in distinguishing between patients with and without CRC, 
and for the time being we do not find it to be an acceptable 
alternative to FS as the initial examination.
One of the most important strengths of our study, is 
that its participants were representative of the patient 
population targeted for use of Hemoccult Sensa® in 
Denmark. By excluding patients with known established 
CRC risk factors, the risk profile among study subjects 
was homogeneous. This is particularly important since 
the predictive value of a test depends on the prevalence of 
the disease in the population, and the prevalence of CRC 
is expected to be less in a population without established 
Table 2 Primary diagnoses at discharge of the 256 study patients 
by hemoccult sensa® result
Primary diagnosis  Positive 
(number)
Negative 
(number)
Colorectal cancer 6 2
Adenoma 10 mm 6 6
Adenoma 10 mm 4 26
nonneoplastic polyps 6 24
normal colon and rectum 22 98
Diverticular disease 7 33
Diverticulitis sequelae 1 2
Colitis
  Crohn’s disease 0 1
  Ulcerative colitis 0 0
  Others 3 5
Angiodysplasia 2 1
Lymphoma 0 1
Total 57 199
Table 3 Tumor site and stage and hemoccult sensa® test results 
for the eight patients with colorectal cancer
Tumor site  Tumor stage  Hemoccult 
Sensa®
Rectum Dukes’ stage B Positive
Rectum Dukes’ stage B Positive
sigmoid colon Dukes’ stage B Positive
sigmoid colon Adenocarcinoma in  
an adenoma (T1)a
Positive
Ascending colon Dukes’ stage D negative
Coecum Dukes’ stage B Positive
Coecum Dukes’ stage B Positive
Coecum and right 
flexure 
Dukes’ stage unknown.  
The patient had peritoneal 
dissemination
negative 
 
Note: aTNM classification.Clinical Epidemiology 2009:1 123
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CRC risk factors than in a population with established CRC 
risk factors.17
Also, the study focused on patients who did not report 
rectal bleeding. The probability of CRC in patients with 
visible rectal bleeding is higher than in patients without 
visible rectal bleeding, and visible rectal bleeding increases 
the likelihood of a positive FOBT.18 Analysis of a pooled 
sample of patients both with and without visible rectal 
bleeding may not have provided useful information about 
the test’s value in each subgroup.
Several potential study weaknesses must be noted. 
We attempted to control for differential recall by selecting 
patients on the basis of symptoms experienced and reported in 
the questionnaire before the first visit to the surgical outpatient 
clinics. We cannot exclude some selection bias, because a part 
of the 735 additional patients without visible rectal bleeding 
might have been referred directly to colonoscopy due to the 
severity or duration of the symptom. However, the prevalence 
of CRC among these additional patients was only slightly 
different from the prevalence in the study population.
We included patients regardless of whether they had 
undergone a FOBT on the recommendation of their general 
practitioner. It is possible that patients with a negative 
Hemoccult Sensa® test performed in the general practice 
setting may have been less likely to receive a referral to a 
surgical outpatient clinic, while patients with severe symp-
toms were more likely to be referred. If all patients who had 
a Hemoccult Sensa® test at the recommendation of their 
general practitioners were uniformly referred to the hospital 
clinics, the proportion of study participants with a negative 
Hemoccult Sensa® may have been higher.
For a number of reasons, our calculation of the sensitivity 
of Hemoccult Sensa® for CRC is likely to be overestimated. 
First, because of the selective approach used in the standard 
diagnostic regimen, colonoscopy was performed in only 
about half of study patients. If all patients had undergone 
colonoscopy, we may have diagnosed more cases of proximal 
CRC. Second, a cancer missed by Hemoccult Sensa® might 
not have been detected within our study’s follow-up period.19 
Finally, CRC and adenomas are more likely to bleed than 
normal colon mucosa; interruption of anticoagulant therapy 
during stool collection was considered too risky, and this 
may have increased the rate of positive tests in especially 
study patients with neoplasm.
To reduce the false-positive rate from ingested peroxidase, 
it is recommended that dietary and medication restrictions be 
imposed three days prior to starting the Hemoccult Sensa® 
test.20 As we were unable to monitor patient adherence to 
these restrictions, low compliance may have contributed 
to the relatively low specificity and PPV for CRC.
Adenomas smaller than 10 mm were more prevalent 
in patients with a negative Hemoccult Sensa® test than in 
patients with a positive test (13.1% vs 7.0%), suggesting 
that such adenomas may be found by chance, as indicated 
in another study.21
An earlier study found that FOBT has a low sensitivity 
for detecting rectal cancer.11 We were not able to confirm 
or disprove this finding, owing to our study’s limited 
sample size; however, all patients with rectal cancers had 
a positive Hemoccult Sensa®. This concordance may arise 
because Hemoccult Sensa® is a more sensitive test than 
Hemoccult and Hemoccult II.22,23
Our estimated values of sensitivity, specificity, and PPV 
are consistent with those reported previously for different 
patient populations.13,14,24 A study which examined Hemoccult 
Sensa® in a patient sample with the same CRC prevalence as 
in our study also found the same value for sensitivity. Unlike 
ours, that study included patients with one or fewer weekly 
episodes of visible bright red blood per rectum, thereby 
increasing the likelihood of a positive Hemoccult Sensa®.14
Our PPV for CRC was similar to that reported for 
patients undergoing routine screening.24 While this finding 
was unexpected, it may be explained by the fact that the vast 
majority of patients in the screening population were men, 
who are at increased risk of advanced polyps and cancers.25 
Our estimates of sensitivity, specificity, and PPV were very 
similar to that found in one study which evaluated the less 
sensitive test Hemoccult II in referred symptomatic patients. 
Unlike ours, that study included patients with established 
CRC risk factors and patients with rectal bleeding.13
In conclusion, we found Hemoccult Sensa® only to have 
relatively acceptable sensitivity and specificity for CRC in 
symptomatic outpatients without known established CRC 
risk factors presenting without visible rectal bleeding. 
Moreover, a considerable number of patients with a positive 
test had no significant colorectal pathology. Thus, we do not 
find that Hemoccult Sensa® is an acceptable alternative to FS 
as the initial examination in symptomatic patients without 
known established CRC risk factors presenting without rectal 
bleeding, especially because FS is a safe examination, has a 
relatively high sensitivity for CRC and can be performed in 
outpatients without sedation and analgesia.
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